Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma

Video

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content